Clinical trialsCompany release

MetaVia sets out liver pipeline, with FDA talks planned on vanoglipel-resmetirom combination

🇺🇸 MetaVia Inc. (MTVA) · Thu 05 Nov 2026

The US biotech's November 2026 corporate presentation reports interim DA-1726 liver-fat data and lays out a timeline running into 2027.

MetaVia has published a corporate presentation focused on its two clinical-stage liver and metabolic assets, DA-1726 and vanoglipel. It includes interim data for DA-1726 and Phase 2a findings for vanoglipel in metabolic dysfunction-associated steatohepatitis (MASH).

For DA-1726, the company reports interim Part 3B data showing a liver-fat reduction of about 68% at Day 109. For vanoglipel, it cites reductions in alanine aminotransferase (ALT) in MASH patients in its Phase 2a study. The summary of the presentation does not give further detail on ALT figures or study design.

On the regulatory side, MetaVia plans to meet the US Food and Drug Administration in the second half of 2026 to discuss combining vanoglipel with resmetirom. It expects to start a Phase 2a combination study in the first half of 2027. A Phase 2 trial of DA-1726 in metabolic dysfunction and alcohol-related liver disease (MetALD) and alcohol-related liver disease (ALD) is planned for the second half of 2027.

The company reported $12.6 million in cash at 30 June 2026. The presentation's timelines therefore rest on a modest cash position as of that date.

What it means for your team

  • The planned FDA meeting on the vanoglipel-resmetirom combination is the next regulatory milestone; its outcome will shape the design of the 2027 Phase 2a study.
  • The interim DA-1726 liver-fat result is early-stage data from a company presentation, not a peer-reviewed or regulatory-reviewed dataset.
  • The MetALD/ALD Phase 2 plan for 2H 2027 signals a move into liver indications that are less crowded than MASH.
  • Cash of $12.6M at 30 June 2026 is a relevant factor for partners and payers assessing whether the timelines are achievable.

Company's press release (SEC filing): MetaVia Inc. ↗

Article written by VigiEye from the official source (MetaVia Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →